Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — Presentation (February 2026)
10 slides from Clearpoint Neuro's investor presentation, Feb 5, 2026
Slide 1: Assets
ASSETS Current Assets: Cash and cash equivalents $ 2,938,212 Current portion of restricted cash 130,000 Accounts receivable, net 1,647,300 Inventory, net 2,014,334 Prepaid expenses and other current assets 1,061,735 Total Current Assets 7,791,581 Property and Equipment, Net 85,587 Other Assets: Rest
Slide 2: Consolidated Statement of Operations and Comprehensive Loss
The accompanying notes to the consolidated financial statements is an integral part of these statements. CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS YEAR ENDED DECEMBER 31, 2024
Slide 3: Consolidated Statement of Change in Stockholders' Deficit
The accompanying notes to the consolidated financial statements is an integral part of these statements. CONSOLIDATED STATEMENT OF CHANGE IN STOCKHOLDERS’ DEFICIT YEAR ENDED DECEMBER 31, 2024
Slide 4: Consolidated Statement of Cash Flows
The accompanying notes to the consolidated financial statements is an integral part of these statements. CONSOLIDATED STATEMENT OF CASH FLOWS YEAR ENDED DECEMBER 31, 2024
Slide 5: Note 1—Description of business
The accompanying notes to the consolidated financial statements is an integral part of these statements. Note 1—Description of business Nature of Business and Basis of Consolidation – The consolidated financial statements of IRRAS Holdings, Inc. and Subsidiaries (together the “Company”) include the
Slide 6: Note 4—Convertible promissory note
Note 4—Convertible promissory note During 2024, the Company entered into convertible promissory notes (“2024 Convertible Notes”) with certain investors in exchange for an aggregate principal amount of $6,330,203. The 2024 Convertible Notes accrue simple interest at a rate of 5% per annum and mature
Slide 7: Note 5—Capital structure
Note 5—Capital structure In accordance with the Company’s Amendment to Certificate of Incorporation dated September 15, 2023, the Company is authorized to issue 3,000,000 shares of $0.0001 par value common stock. There were 1,835,095 shares of common stock issued and outstanding at December 31, 2024
Slide 8: Other information related to the leases
As of December 31, 2024, other information related to the leases was as follows:
Slide 9: Note 7—Income taxes (continued)
Note 7—Income taxes (continued) The significant components of deferred tax assets and liabilities as of December 31, 2024 are as follows:
Slide 10: Deferred tax assets valuation allowance and net operating loss carryforwards
The Company has determined it is more likely than not that its deferred tax assets will not be realized. Accordingly, a valuation allowance has been recorded at December 31, 2024 to fully offset the deferred tax asset of $34,042,351. As of December 31, 2024, the Company had approximately $81,427,000